 |
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Name:
|
ABT 418
|
|
Development Status:
|
investigational in U.S.
|
|
FDA Phase:
|
Discontinued
|
|
Primary Medical Role:
|
A potent nicotinic agonist shown to enhance memory and
learning in rats and monkeys.
|
Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse
PA. Acute effects of the selective cholinergic channel
activator (nicotinic agonist) ABT-418 in Alzheimer's
disease. Psychopharmacology (Berl). 1999 Mar;142(4):334-42. Abstract
Prendergast MA, Jackson WJ, Terry AV Jr, Decker MW,
Arneric SP, Buccafusco JJ. Central nicotinic receptor
agonists ABT-418, ABT-089, and (-)-nicotine reduce
distractibility in adult monkeys. Psychopharmacology
(Berl). 1998 Mar;136(1):50-8.
Abstract
Warpman U, Nordberg A. Epibatidine and ABT 418 reveal
selective losses of alpha 4 beta 2 nicotinic receptors in
Alzheimer brains. Neuroreport. 1995 Nov 27;6(17):2419-23. Abstract
Buccafusco JJ, Jackson WJ, Terry AV Jr, Marsh KC, Decker
MW, Arneric SP. Improvement in performance of a delayed
matching-to-sample task by monkeys following ABT-418: a
novel cholinergic channel activator for memory enhancement.
Psychopharmacology (Berl). 1995 Aug;120(3):256-66. Abstract
Arneric SP, Sullivan JP, Decker MW, Brioni JD, Bannon AW,
Briggs CA, Donnelly-Roberts D, Radek RJ, Marsh KC, Kyncl
J, et al. Potential treatment of Alzheimer disease using
cholinergic channel activators (ChCAs) with cognitive
enhancement, anxiolytic-like, and cytoprotective
properties. Alzheimer Dis Assoc Disord. 1995;9 Suppl 2:50-
61. Abstract
Decker MW, Curzon P, Brioni JD, Arneric SP. Effects of ABT-
418, a novel cholinergic channel ligand, on place learning
in septal-lesioned rats. Eur J Pharmacol. 1994 Aug 11;261
(1-2):217-22. Abstract
Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D,
Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams
P, Garvey DS, et al. (S)-3-methyl-5-(1-methyl-2-
pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic
ligand with cognition-enhancing and anxiolytic activities:
I. In vitro characterization. J Pharmacol Exp Ther. 1994
Jul;270(1):310-8. Abstract
Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ,
Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT,
et al. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole
(ABT 418): a novel cholinergic ligand with cognition-
enhancing and anxiolytic activities: II. In vivo
characterization. J Pharmacol Exp Ther. 1994 Jul;270
(1):319-28. Abstract
|
Home
